Vedanta strikes deal with Janssen for IBD therapy
This article was originally published in Scrip
Executive Summary
Janssen, a subsidiary of Johnson & Johnson, has entered a license agreement with Vedanta Biosciences to develop the latter firm's lead microbiome pharmaceutical candidate, VE202, for inflammatory bowel disease (IBD).